SAB Biotherapeutics (SABS) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free SABS Stock Alerts $3.50 -0.13 (-3.58%) (As of 11:05 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 6, 2024 | globenewswire.comSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsApril 17, 2024 | msn.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 16, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | globenewswire.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 8, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingApril 4, 2024 | markets.businessinsider.comSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy RatingApril 4, 2024 | globenewswire.comSAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 29, 2024 | globenewswire.comSAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 25, 2024 | markets.businessinsider.comSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock DropsMarch 25, 2024 | globenewswire.comSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentFebruary 23, 2024 | globenewswire.comSAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 2, 2024 | marketwatch.comSAB Biotherapeutics Names Samuel Reich Chief ExecutiveFebruary 2, 2024 | markets.businessinsider.comSAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEOFebruary 2, 2024 | finance.yahoo.comSAB Biotherapeutics Announces Executive Leadership ChangeJanuary 29, 2024 | marketbeat.comTrading was temporarily halted for "SABS" at 09:01 AM with a stated reason of "LULD pause."January 24, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 23, 2024 | finance.yahoo.comSAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)January 5, 2024 | finance.yahoo.comIndividual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last weekJanuary 5, 2024 | marketbeat.comTrading was temporarily halted for "SABS" at 07:01 PM with a stated reason of "News pending."January 3, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitJanuary 2, 2024 | finance.yahoo.comSAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitDecember 8, 2023 | finance.yahoo.comHere's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock NowDecember 1, 2023 | msn.comVerifyMe And 3 Other Stocks Under $2 Insiders Are BuyingNovember 29, 2023 | finance.yahoo.comSAB Biotherapeutics Starts Human Clinical Trial of Diabetes TreatmentNovember 29, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In AustraliaNovember 29, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNovember 20, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNovember 20, 2023 | finance.yahoo.comSAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNovember 14, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNovember 14, 2023 | msn.comSAB Biotherapeutics GAAP EPS of -$0.10November 14, 2023 | finance.yahoo.comSAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in FinancingNovember 14, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNovember 14, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNovember 9, 2023 | finance.yahoo.comSAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNovember 6, 2023 | msn.comSAB Biotherapeutics files to sell 412.7M units to noteholdersOctober 24, 2023 | finance.yahoo.comSAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerOctober 19, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: SAB Biotherapeutics (SABS), Elevance Health (ELV)October 19, 2023 | finance.yahoo.comSAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesOctober 6, 2023 | markets.businessinsider.comSAB Biotherapeutics’ Financial Stability and Potential Growth: A Comprehensive Analysis of Edward White’s Buy RatingOctober 6, 2023 | markets.businessinsider.comSecured Financing and Promising Clinical Developments Bolster Buy Rating for SAB BiotherapeuticsOctober 5, 2023 | finance.yahoo.comSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsOctober 5, 2023 | finance.yahoo.comSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsOctober 3, 2023 | finance.yahoo.comSAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes TreatmentOctober 2, 2023 | finance.yahoo.comEXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes CandidateOctober 2, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs SABS Media Mentions By Week SABS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SABS News Sentiment▼0.000.42▲Average Medical News Sentiment SABS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SABS Articles This Week▼01▲SABS Articles Average Week Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRIS News Today SGMO News Today ACHL News Today INKT News Today QNCX News Today PLUR News Today BCLI News Today CYTH News Today SRZN News Today OKYO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SABS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
